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Abstract
Human neural stem cells (hNSC) represent an essential source of renewable brain cells for both experimental studies and
cell replacement therapies. Their relatively slow rate of proliferation and physiological senescence in culture make their use
cumbersome under some experimental and pre-clinical settings. The immortalization of hNSC with the v-myc gene (v-
IhNSC) has been shown to generate stem cells endowed with enhanced proliferative capacity, which greatly facilitates the
study of hNSCs, both in vitro and in vivo. Despite the excellent safety properties displayed by v-IhNSCs – which do not
transform in vitro and are not tumorigenic in vivo – the v-myc gene contains several mutations and recombination
elements, whose role(s) and effects remains to be elucidated, yielding unresolved safety concerns. To address this issue, we
used a c-myc T58A retroviral vector to establish an immortal cell line (T-IhNSC) from the same hNSCs used to generate the
original v-IhNSCs and compared their characteristics with the latter, with hNSC and with hNSC immortalized using c-myc wt
(c-IhNSC). T-IhNSCs displayed an enhanced self-renewal ability, with their proliferative capacity and clonogenic potential
being remarkably comparable to those of v-IhNSC and higher than wild type hNSCs and c-IhNSCs. Upon growth factors
removal, T-IhNSC promptly gave rise to well-differentiated neurons, astrocytes and most importantly, to a heretofore
undocumented high percentage of human oligodendrocytes (up to 23%). Persistent growth-factor dependence, steady
functional properties, lack of ability to generate colonies in soft-agar colony-forming assay and to establish tumors upon
orthotopic transplantation, point to the fact that immortalization by c-myc T58A does not bring about tumorigenicity in
hNSCs. Hence, this work describes a novel and continuous cell line of immortalized human multipotent neural stem cells, in
which the immortalizing agent is represented by a single gene which, in turn, carries a single and well characterized
mutation. From a different perspective, these data report on a safe approach to increase human neural stem cells
propagation in culture, without altering their basic properties. These T-IhNSC line provides a versatile model for the
elucidation of the mechanisms involved in human neural stem cells expansion and for development of high throughput
assays for both basic and translational research on human neural cell development. The improved proclivity of T-IhNSC to
generate human oligodendrocytes propose T-IhNSC as a feasible candidate for the design of experimental and, perhaps,
therapeutic approaches in demyelinating diseases.
Citation: De Filippis L, Ferrari D, Rota Nodari L, Amati B, Snyder E, et al. (2008) Immortalization of Human Neural Stem Cells with the c-Myc Mutant T58A. PLoS
ONE 3(10): e3310. doi:10.1371/journal.pone.0003310
Editor: Patrick Callaerts, Katholieke Universiteit Leuven, Belgium
Received July 8, 2008; Accepted August 27, 2008; Published October 2, 2008
Copyright:  2008 De Filippis et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The studies performed in this paper were funded by ONLUS association Neurothon, Cariplo and by Ministero della Sanita ` which provided essential
financial support for all the experiments.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: defilippis.lidia@hsr.it
Introduction
Neural stem cells (NSC) are pivotal players in the development
of the central nervous system development, maintenance and
repair [1–7]. As such, they hold great potential in the areas of drug
discovery, cell therapy, replacement and cell-mediated gene
therapy.
Human neural stem cells (hNSCs) have been shown to provide a
plentiful, renewable source of neural for cell replacement.
Notwithstanding, as expected for somatic stem cells, following a
finite number of cell divisions in culture, hNSCs will eventually
undergo growth arrest and senescence. This limits their exploita-
tion in the field of biotechnology and in pharmacological studies
relying on large scale, high-throughput assays. In this perspective,
an alternative source of human brain cells, bearing all the features
of wild type hNSCs and possessing unlimited expandability, would
be of immense value for modelling studies in neuroscience, drug
discovery and cell therapy.
We and others have shown how oncogene-mediated immortal-
ization of human neural precursors/stem cells provides an initial
attempt to overcome these limitations, leading to the establishment
of immortal hNSC lines [5,8]. Despite these results, it is highly
desirable to obtain immortalized neural stem cell lines, in which
the immortalizing agent is better characterized and predictable in
its effects, so that the immortalized lines will mimic the behavior of
normal hNSCs as closely as possible also, tentatively, to be used in
a cell therapy context.
We have recently described the immortalization of wild type
hNSCs with v-myc, resulting in the establishment of a stable
neural stem cell line (v-IhNSC) endowed with the ability to
originate mature functional neurons and conspicuous amounts of
oligodendrocytes in vitro [9]. This line never showed any sign of
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ping those of its wild-type counterpart, and strict growth factor
dependence. Given the well documented oncogenic potential of v-
myc [10,11] and the fact that its regulatory mechanisms remain to
be fully elucidated, we decided to improve this strategy by looking
for an immortalizing, well-characterized gene which was as similar
as possible to its wild-type gene while, at the same time, possessing
most of the advantages of v-myc.
In this perspective, we argued that a candidate immortalizing
gene, containing a single, specific mutation, would represent an
optimal candidate to obtain novel IhNSCs. To accomplish this goal,
wedecidedtoattemptimmortalizationofwild typehNSCsbymeans
of a c-mycT58A expressing retroviral vector [12] and compared the
properties of the resultant immortalized cells (T-IhNSC) to that of
their normal counterparts, as well as to those of both v-myc (v-
IhNSC) and c-myc wt (c-IhNSC) immortalized human neural stem
cells [9]. The T58A c-myc mutant was chosen as a candidate
immortalizing agent in considering that the intracellular levels of c-
myc protein play a critical role in proliferation and that the stability
and accumulation of c-myc are regulated by multiple Ras effector
pathways. Since the phosphorylation of the Thr58 residue in c-myc
is important for its degradation – for the former acts as a recognition
site for the ubiquitin ligase Fbw7 – the mutation of Thr58 to alanine
found in T58A c-myc results in a more stable c-myc protein, with a
consequent increase in its intracellular levels, reduced apoptosis and
increased proliferation activity [11,13–22]. Accordingly, several v-
myc genes from transforming retroviruses harbor mutations at the
Thr58 residue [23,24]. Similarly, the c-myc gene translocated in
Burkitt’s lymphoma, frequently carries a mutation at the Thr58
residue [15,17,19–21] and shows reduced pro-apoptotic function in
both cell culture assays and animals [11,13,16,19,20].
In this study, we report for the first time that T58A c-myc
successfully immortalizes hNSCs and that these T-IhNSCs
proliferate faster than their wild-type counterpart and c-IhNSC
immortalized cells, but less than v-IhNSCs. Notably, T-IhNSC
cells rapidly stop dividing upon removal of growth factors and
reach terminal differentiation within 14 days in vitro, similar to
normal non-immortalized cells (hNSC). Moreover, their differen-
tiation profile appears to encompass a unique ability to generate
an extremely high percentage of oligodendrocytes and of neuronal
cells, in a fashion comparable to that v-IhNSCs [9]. Thus, by this
work we introduce a novel cell line of human neural stem cells,
which have been immortalized by a gene that carries a single, well
characterized mutation and putative mechanism of action. In
addition, these T-IhNSCs bear similar, useful functional features –
multipotentiality, stability, neuronal and oligodendroglia differen-
tiation and improved growth rate – as compared to previously
established v-IhNSCs, but bear a significantly lesser probability of
tumorigenic transformation.
Materials and Methods
Propagation and differentiation of neural stem cells
The parental human neural stem cells (hNSCs) used in this
study have been reported previously [25]. Briefly, cells were
derived from the diencephalic and telencephalic brain regions of a
10.5-week gestational-age aborted Caucasian human fetus and
cultured in the presence of 20 ng/ml of human recombinant EGF
and and 10 ng/ml of FGF2 (Tebubio, Milan, Italy), in NS-A basal
serum-free medium (Euroclone, Irvine, Scotland) containing
2 mM L-glutamine, 0.6% glucose, 9.6 ug/ml putrescine, 6.3 ng/
ml progesterone, 5.2 ng/ml sodium selenite, 0.025 mg/ml insulin,
0.1 mg/ml transferrin (sodium salt, grade II; Sigma) [25].
To induce hNSC differentiation, individual spheres were
mechanically dissociated and cells were transferred at a density
of 2.5610 ˆ4 cells/cm
2 onto matrigel (Sigma)-coated chamber-slides
in the presence of 20 ng/ml FGF2. After 72 hrs, cultures were
shifted to NS-A control medium (CM) containing 2% fetal calf
serum (FCS) and grown for two weeks. This treatment resulted in
a mixed culture of neural cells containing astrocytes, neurons and
oligodendrocytes [25]. Afterwards, they were fixed and processed
for immunostaining at appropriate time-points.
Retroviral infections
Retroviral constructs utilized are based on p-Babe, a replica-
tion-defective retroviral vector conferring resistance to neomycin.
Constructs encoding either c-myc or c-myc T58A were used to
transduce hNSCs at 17 passages from the primary culture. A mock
vector was used as a control. v-IhNSCs were generated by
immortalization with the v-myc gene [9].
Parental hNSCs were first expanded with growth factors
(EGF+FGF2) as neurospheres up to passage 17. After mechanical
dissociation, the cells were cultured in EGF+FGF2 containing
medium for 24 hours in order to obtain a culture enriched in stem
cells. Retroviral transduction was then performed by a repeated-
infection procedure: a pretransduction period in the presence of
EGF and FGF2 (days 0–2) was used to obtain an adherent culture
growing on a laminin-coated plastic substrate while division was
stimulated by growth factors. Retroviral vector supernatant (GF
medium) supplemented with polybrene (8 ug/ml) was filtered and
then added to the cells. Three rounds of infection were performed
in a period of 36 hrs, after which the cells were returned to fresh
GF-containing medium and expanded as neurospheres (in
suspension) for 9 passages. Selection of neomycin-resistant
transduced cells was carried out with 1200 ug/ml G418. Aliquots
of these non-clonal cell lines were cryopreserved in GF culture
medium containing 10%DMSO.
To induce IhNSC differentiation, individual spheres were
mechanically dissociated and were transferred at a density of
1610 ˆ4 cells/cm
2 onto laminin (Roche)-coated glass coverslips in
the presence of 20 ng/ml FGF2. After 72 hrs, cultures were
shifted to serum-deprived NS-A control medium (CM) and grown
for up to two weeks to obtain a mixed culture of neural cells
containing astrocytes, neurons and oligodendrocytes [26].
Clonal analysis
IhNSC neurospheres were mechanically dissociated (.200
extrusion cycles through a p200, Gilson yellow tip pipette) to yield
a single cell suspension. Cells were plated by serial, limiting dilution
[27] to obtain a statistical distribution of ,1 cell/well in 96 well plates
(BD Biosciences), in complete growth medium containing EGF and
FGF-2. Single wells were scored by direct visualization under a phase
contrast microscope and only those containing one cell per well were
taken into account. Slightly less than 40% of the wells containing
single cells gave rise to a clonal cell line. Three of these clones were
chosen as representative and characterized by growth curve analysis
and differentiation assay, yielding comparable results.
Clonogenic assay
Neurospheres from different cultures were dissociated and single
cells were plated at decreasing densities in 24 well plates (BD
Biosciences) precoated with poly-lisine in complete medium
containing EGF and FGF-2. IhNSC cells were plated at 5000,
2500 and 1000 cells per well. After 4 days in vitro, the fraction of
wells positive for neurosphere formation was quantified. The data
are presented as the percentage of neurospheres of the total number
of plated cells: every value corresponds to the the average of three
c-Myc T58A Immortal Stem Cells
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well was chosen as representative, as similar results came from the
other two cell densities. The experiment was repeated twice [27].
Viability assay
Upon mechanical dissociation of expanding neurospheres from
c-IhNSC, T-IhNSC and v-IhNSC cultures, 200.000 cells from
each culture were plated in separate T25 flasks containing 5 ml of
basal culture medium. Three T25 flasks were simultaneously
plated for each culture and live cells were counted at 24, 48 and
72 hrs by trypan blue staining in a Burker chamber. The
experiment was repeated twice.
Immunocytochemistry
Cultures were fixed in freshly prepared, buffered 4% paraformal-
dehyde. After blocking with 10% normal goat serum, the cultures
wereincubatedovernightat4uCwith thefollowingantibodies (mAb,
monoclonal; pAb, polyclonal): b-tubulin isotypeIII (mAb, MMS-
435P Babco, 1:400), glial fibrillar acidic protein (GFAP pAb, Dako
1:400), galactocerebroside C (Gal-C, mAb MAB345 Chemicon
1:100), O4 (mAb, MAB342 Chemicon 1:100), tyrosine-hydroxylase
(TH mAb, Novocastra NCL-TH, 1:100), gamma aminobutirric acid
(GABA pAb, Sigma, 1:1000), glutamatergic acid (GLUTAMATE
pAb, Sigma 1:3000), microtubule-associated protein 2 (MAP2 mAb,
Chemicon 1:400), KI67 nuclear antigen (pAb, Novocastra NCL-
Ki67p 1:1000), vimentin (mAb, Chemicon 1:400), MAP5 (mAb
Immunological Science 1:400).
After removal of the primary antibodies and repeated washes
with PBS, cultures were incubated for 45 minutes at room
temperature with secondary antibodies Alexa 488 (A11008
Molecular Probe, anti-rabbit 1:1000) and/or Alexa 546 (A11030
Molecular Probe, anti-mouse 1:1000). Samples were then coloured
with dapi (0,3 mg/ml, Roche) for nuclear staining and rinsed with
PBS for mounting and analyses. Microscopic examination and
photography of specimens were performed with a Zeiss Axiovert
200 direct epifluorescence microscope.
Data are reported as percentages of labeled cells over the total
number of nuclei +/2 the standard error of the mean (SE). An
average total amount of 3000 cells (identified by Dapi nuclear
staining) was counted randomly from 2 coverslips per condition in
each experiment. Each value represents the average of three
independent experiments.
Results
Transduction of hNSCs with c-mycT58A enhances
proliferation and expansion
Previous data from Cartwright et al. [12] showed that sustained
expression of c-myc T58A in murine ES cells elicits increased self-
renewal and maintenance of pluripotency. To test if c-myc T58A
could be used as an immortalizing gene, hNSCs established
previously from a human fetus forebrain at 10.5 pcw (parental
cells; [25]) were transduced with a retroviral construct expressing
wild type c-myc or c-myc T58A [17]. Transgene expression was
confirmed by RT-PCR (not shown). After selection in neomycin-
containing medium, T58A (T-IhNSC) and c-myc (c-IhNSC) lines
were found to proliferate and to form neurospheres in the presence
of EGF and FGF2, similar to their parental cells [25]. However,
while c-IhNSC expressed an unchanged growth rate kinetic, the
growth of T-IhNSC increased significantly, approaching an
estimated doubling time of 4–5 days (Fig. 1 A) as compared to
the standard 8–10 days of their parental cells [25]. The increased
growth rate of T-IhNSCs was only slightly lower than the 3–4 days
observed in the same cells previously immortalized using v-myc (v-
IhNSCs)[9]. In turn, mock-infected cells underwent senescence
after few (2–3) passages from antibiotic selection, re-emphasizing
the well-known sensitivity of wild type hNSCs cells to extensive
and somewhat harsh transduction manipulations.
As hoped, immortalized T-IhNSC cells did retain strict growth
factor dependence, shown by the fact that, upon removal of EGF
and bFGF from the growth medium, they underwent loss of
proliferation ability (Fig. 1B). In addition to their proliferative
capacity, an essential property of bona fide stem cells is their self-
renewal potential, which can be demonstrated in neural stem cell
cultures by observing a linear cell growth kinetic under the
appropriate neurosphere assay conditions and in long-term
cultures [28]. Since Immortalization is expected to perpetuate
the ability of stem cells to self-renew [29], we subjected T-IhNSCs
neurospheres to long-term, sequential passaging as bulk cultures,
in order to determine their extensive self-renewal capacity and
related steady growth properties. As expected T-IhNSCs were
easily maintained and steadily expanded in culture for up to at
least 120 passages, differently from their parental hNSCs, which
undergo spontaneous senescence after 45–50 passages [25]. T-
IhNSCs’ growth rate was stable over passaging and so was their
strict growth factor dependence.
To obtain a direct evidence of the improved self-renewal
capacity of T-IhNSC we performed a clonogenic, neurosphere
assay. As expected, the clonogenic index of T-IhNSC cultures after
dissociation (18.8861.43 S.E.% of the total of plated cells) was
somewhat similar to that of v-IhNSC (20.2261.33 S.E.%), but
significantly increased with respect to c-IhNSC (11.3361.07
S.E.%) or to parental cells [30,31] (Fig. 1C).
These results were integrated by a viability assay, which
demonstrated comparable percentages of surviving cells in T-
IhNSC and v-IhNSC clonogenic cultures, at least 50% higher as
compared to c-IhNSC cells (Fig. 1D) or parental cells [30].
Altogether, these findings demonstrate that by T58 c-myc
transduction of hNSCs, we have generated a novel immortalized
hNSCs cell line endowed with rapid proliferation capacity, strict
and increased and extended self-renewal ability.
Cell cycle analysis
To investigate whether enhanced cell proliferation in T-IhNSC
cells was due to an increased proliferating cell fraction or to
shortening of the duration of the cell cycle, we analysed cell
distribution throughout cell cycle phases. Cytofluorimetric analysis
showed that the average T-IhNSC and c-IhNSC cell cycle times
were comparable (approximately 50–55 hrs), whereas v-IhNSC
entertained a significantly faster cell cycle (about 40 hrs). Of note,
over 25% of cells were actively engaged in the S phase in all of the
three immortalized cultures, as compare to about 2.5% in parental
cell cultures (Figure S1). These results point to the conclusion that
T-IhNSC expand faster in number than c-IhNSC cells due to a
higher percentage of viable proliferating cells being produced at
each generation (Fig. 1C, D). Conversely, their lower rate of
amplification in culture as compared to v-IhNSC, is likely due to a
longer cell cycle.
Taken together, these findings show that c-mycT58A-mediated
immortalization of cultured hNSCs leads to the establishment of
immortalized neural cells endowed with an extensive and rapid
proliferation capacity, which retain functional key characteristic of
their parental cells, such as the typical steady growth profile and
growth factor-dependence observed in parental cells.
T58A cells are multipotent
To confirm that the immortal T-IhNSCs lines that we had
established did, in fact, bear the features of hNSCs, we proceeded
c-Myc T58A Immortal Stem Cells
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feature known as multipotency,i.e. the ability to generate all the
three major neural cell types: neurons, astrocytes and oligoden-
drocytes [25]. To do so, we analyzed both bulk population cultures
as well as three clonal cell lines derived from the former by means
of standard limiting dilution techniques [27]. Differentiation of T-
IhNSCs was triggered as typically done with wild type hNSCs, i.e.
by growth factor removal and was investigated using antibodies
against lineage-specific, pan-neural antigens. Anti-MAP5 (Figure
S2), anti-bIII-tubulin and anti-microtubule associated protein 2
(MAP2) were used to label neurons, anti-vimentin (Figure S2) and
anti-GFAP served to detect astrocytes, and anti-O4 (Figure S2)
and anti-GalC marked oligodendrocytes.
As observed in parental hNSCs (Fig. 2a–b, Figure S2a–c), c-
IhNSCs (Fig. 2c–d, Figure S2d–f) and v-IhNSCs (Fig. 2g–h, Figure
S2l–n), both bulk cultures and clonally expanded T-IhNSC
(Fig. 2e–f, Figure S2g–i) cells retained the ability to give rise to
the three main neural cell types. Interestingly, a double
immunofluorescence analysis of T-IhNSC-derived progenitors
(3div in FGF2) with anti-bIII-tubulin and anti-GFAP showed the
sporadic occurrence of asymmetric divisions (n,0,1% over the
total number of cell divisions, given a frequency of cell divisions
=0.8760.092% over the total cell number) in the differentiating
culture (Figure S3, panel B). With regard to neuronal differenti-
ation, unipolar neurons were recognizable in the T-IhNSC culture
by day 10
th, which extended long, fine processes, bearing
varicosities by day 17
th (Figure S4). This morphology resembled
that of v-IhNSC differentiating cells (Figure S4l-n) [9].
Atday10,bIII-tubulin-IR cellsgeneratedbyT-IhNSCspeakedat
10.7861.89% of the total cell number (Fig. 3A), which was
comparable to parental cells (10.160.43%) [25] or c-IhNSCs (9.79
62.83%) but significantly lower than in v-IhNSC cultures
(19.9665.67%). To assess if this difference corresponded to a lower
percentage of neurons generated by T-IhNSC as compared to v-
IhNSCor,rather,todifferencesinthetimedifferentiationprofile,we
investigated the profile of expression of the late neuronal dendritic
marker MAP2. Unlike bIII-tubulin, the number of cells expressing
the MAP2 dendritic protein in T-IhNSCs cultures (Fig. 3C, e and f),
had already peaked at 14.6862.57% of the total cell number at 10
DIVand thispercentagewasstablymaintainedupto17daysinvitro
(Fig. 3B) as compared with differentiated cultures from parental cells
(2.8260.79%, Fig. 3C, a and b), c-IhNSCs (6.261.07%)(Fig. 3C, c
and d), or v-IhNSCs (12.561.8%) (Fig. 3C, g and h). This points to
the fact that, as compared to other immortalized lines, T-IhNSCs
display a differentiation profile by which the onset of the
differentiation/maturation process occurs earlier. This concept was
supported by findings on the astroglial differentiation in T-IhNSCs.
The astrocytes generated from T-IhNSCs were quite similar to
the astrocytes generated by v-IhNSC cells. They displayed a
typical protoplasmic morphology (Fig. 4B), being strictly GFAP
positive and never co-labelled with bIII-tubulin (Fig. 2 a, c, e, g) –
the latter phenomenon having recently been documented in
Figure 1. Analysis of long-term proliferation in T58A stem cells. A) Growth curve of c-IhNSC, T-IhNSC, v-IhNSCs and mock cultures in the
presence of EGF and FGF2 in the culture medium. The slopes of the curves show how much higher the proliferation rate of IhNSCs cells is than hNSC
cells. At each passage, 200.000 cells were plated and counted when they originated neurospheres. B) Growth curve of c-IhNSC, T-IhNSC, v-IhNSCs in
absence of growth factors. Cells could not be expanded using these conditions. C) Clonogenic assay of c-IhNSC, T-IhNSC, v-IhNSCs. Values correspond
to the average value of two experiments (three samples per experiment). D) Viability assay of c-IhNSC, T-IhNSC cells, IhNSCs at 24, 48, 72 hours from
dissociation of neurospheres and plating of 200.000 cells.
doi:10.1371/journal.pone.0003310.g001
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appeared significantly earlier in T-IhNSC cells as compared to the
other cell lines (Fig. 4A, B). In fact, 65.3620.45 S.E.% of the T-
IhNSCs differentiated cultures (at 3 DIV) were GFAP+ as
compared to 15.4963.03 S.E.% from c-IhNSC or to
1.2560.417 S.E.% from v-IhNSC cells or to 20.565.3 SE%
from hNSC (Fig. 4A). A quantitative analysis of GFAP+ cells at 10
DIV was not possible, as most of the cells were GFAP+ (Fig. 2 a, c,
e, f). This result is consistent with the previous observation of an
early MAP2 expression onset (Fig. 3) and re-emphasizes the
concept that T-IhNSCs undergo earlier differentiation and
maturation as compared to v-IhNSC or c-IhNSC cells. Yet,
different from parental cells and more similar to immortalized v-
IhNSCs, T-IhNSC cells generate a large quantity of well-
differentiated neurons, without the need of supplementing the
differentiation medium with serum.
Analysis of proliferation during differentiation
As discussed above, a critical feature of bona fide neural stem cells
istheirabilitytoceaseproliferation–exceptforsomeresidualmitotic
activity related to astroglial cells and late neural progenitors – and to
have their progeny undergoing terminal differentiation upon growth
factorremovalandplatingontoanadhesionsubstrate[25].Thistrait
ought to be retained by immortal hNSCs, if they are to provide a
Figure 2. Multipotency. Cells from hNSC, c-IhNSC, T-IhNSC and v-IhNSC cells line were differentiated on laminin-coated glass coverslips in the
absence of growth factors (see materials and methods) for 10 (a,c,e,g) and 17 days (b,d,f,h). Immunofluorescence staining showing the presence of
astrocytes (GFAP+, green, a,c,e,g), neurons (b-tubulin+, red, a,c,e,g) and oligodendrocytes (GalC+, red, b,d,f,h). The three major neural lineage markers
were detected in distinct cells of the same cell population of origin, thus demonstrating the multipotency of IhNSCs. DAPI nuclear staining (blue) is
also shown to detect total cells. Magnification 206.
doi:10.1371/journal.pone.0003310.g002
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PLoS ONE | www.plosone.org 5 October 2008 | Volume 3 | Issue 10 | e3310Figure 3. Quantitative analysis of neuronal markers expression during differentiation. A and B) Quantitative analysis of the neuronal
differentiation capacity of h-NSC, c-IhNSC, T-IhNSC and v-IhNSCs cells. Cells were differentiated in adhesion on laminin in the absence of mitogenic
factors and analyzed at 3, 10 and 17 days. Data are expressed as percentages of b-tubulinIII (early neuronal marker) and MAP2+ (which is expressed
later during neuronal differentiation). Magnification 206. Panel C: Immunofluorescence of hNSC (a and b), c-IhNSC (c and d), T-IhNSC (e and f) and v-
IhNSCs (g and h) cell line for MAP2 at 10 (a,c,e and d) and 17 (b,d,f and h) days in vitro. DAPI nuclear staining (blue) is also shown to detect the total
cell number. Magnification 206.
doi:10.1371/journal.pone.0003310.g003
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hNSCs, while providing technical and practical advantages, such as
long term and faster expandability in the absence of concomitant
transformation. Hence we set out to validate this specificaspectof T-
IhNSCs behaviour. Similar to their parental cells, all immortalized
hNSCs did undergo growth arrest upon growth factor starvation,
with scarce residual proliferation being observed. This was
demonstrated by a quantitative immunofluorescence analysis
performed using the proliferation marker KI67 (Fig. 5A). Once
more, in good agreement with the differentiation data, suggesting
that T-IhNSCs undergo early differentiation and maturation in the
absence of growth factors, T-IhNSCs virtually ceased to proliferate
byday17,verysimilartotheirparental cells[25].Atthistime,onlya
small number of mitotic cells could be detected in both cultures
(4.260.7% T-IhNSCs; 4.93%6 1.62 hNSCs). Notably, at the same
time, growth arrest was somewhat incomplete in both v-IhNSC
(10.2561.718%) [9] and c-IhNSC cells (10.8262.72%) (Fig. 5A).
Furthermore, a significant fraction of the residual KI67+ cells in T-
IhNSCs (21.6860.33%) was a simultaneously labelled with the
neuronal precursor marker b-tubulinIII (Fig. 5B), showing that a
significant fraction of the residual proliferating cells were neuronal
progenitors. Taken together, these findings show that T-IhNSC cells
are immortalized but retain quite strict growth factor dependence
and proper differentiation characteristics, which accounts for lack of
transformation in our hands. This critical trait is accompanied by an
apparently enhanced ability of T-IhNSC cells to generate higher
percentages of neurons than their parental cells (Fig. 3 A, B).
An initial analysis of the neuronal phenotypes generated by T-
IhNSCs showed that, fourteen days following the onset of
differentiation, most of the total bIII-tub-IR cells co-labelled with
Figure 4. Analysis of precocious GFAP expression in T58A differentiating cells. A) Quantitative analysis of expression of the astroglial
marker GFAP in progenitor cells (3 days in FGF2) from hNSC, c-IhNSC, T-IhNSC, and v-IhNSC cells. Data are expressed as percentages of GFAP+ cells of
the total number of cells. B) Immunofluorescence staining of hNSC (a), c-IhNSC (b), T-IhNSC (c), and v-IhNSC (d) cells at 3 days in vitro for GFAP. DAPI
nuclear staining (blue) is also shown to detect total cell number. Magnification 206.
doi:10.1371/journal.pone.0003310.g004
c-Myc T58A Immortal Stem Cells
PLoS ONE | www.plosone.org 7 October 2008 | Volume 3 | Issue 10 | e3310the anti-GABA antibody (Fig. 5C). A minority of cells were
glutamatergic, while no TH+ phenotype was detected in the
differentiated progeny. It is worth noting how this pattern is very
similar to that of the parental cells [31], re-emphasizing the
resemblance of the T-IhNSC cells to wild-type hNSCs.
T58A cells as a source of mature oligodendrocytes
A perusal of the literature on hNSCs, readily underlines how
one of the major hurdles in this area has been to obtain the
differentiation of hNSCs into a meaningful and useful amount of
oligodendrocytes [31–34]. Strikingly, the T-IhNSC cells described
here, display a unique capacity to generate bona-fide oligoden-
drocytes, which rarely appear in differentiated parental cultures.
The genesis of numerous cells immunoreactive for GalC in T-
IhNSC was readily apparent by 17 days after removal of
mitogenis. At this time, oligodendrocytes appeared as star-shaped
cells, with numerous, elongated and branched processes (Fig. 2),
which matured to acquire a ‘‘myelinating’’ morphology by 24 days
in vitro (Fig. 6B). By this time (24 div) as many as 18.5964.69% of
the total cells became GalC or O4-IR versus 13.4162.6% in v-
IhNSC or 7.2364.77 in c-IhNSC % (Fig. 6A).
These findings describe T-IhNSCs as a stable, fast-growing
multipotent human NSC line cell, with an enhanced ability to
generate neuronal and oligodendroglia cells which, in a way
heretofore unprecedented, preserve a behaviour strictly reminis-
cent of wild-type hNSCs.
Discussion
Renewable and stable sources of human brain cells, bearing all
of the features of multipotent neural stem cells, provide an
invaluable tool in basic and preclinical studies in neuroscience
[35]. In this context, we recently reported the establishment of v-
myc, conditionally immortalized, human neural stem cell lines,
which retain strict mitogen dependence in culture and generate
mature neuronal and glial progeny including, for the first time, a
significant percentage of oligodendroglial cells. [5].
In considering that v-myc is a well-known super-oncogene,
bearing different mutations of the c-myc gene at multiple sites, we
set out to find an alternative, immortalizing agent that retained a
structure closer to the wild-type allele. The c-myc T58A gene
bears a single mutation as compared to wild type c-myc and has
never been used before to immortalize cells. The T58A mutation
has been identified in several cases of Burkitt’s lymphomas. It is
involved in the stabilization of c-myc, likely by impairing the rapid
proteolysis of c-myc through Thr-58 phosphorylation [17]. Here,
we report the first successful attempt to use c-myc T58A to
establish an immortal cell line from human neural stem cells of
fetal origin. The resulting cell line (T-IhNSC) has the capacity to
generate unlimited quantities of conditionally immortalized
hNSCs, which can then be differentiated into mature neurons,
astroglia and significant numbers of oligodendroglial cells. The
characteristics of this cell line were compared to their wild type
human neural stem cells and to hNSCs immortalized with c-myc
wt or v-myc [9], using the same source of fetal neural stem cells.
This allows to determine any similarities and potential advantages
of T-IhNSCs, in addition to this line having been established using
a much lesser mutated and better characterized c-myc mutant.
Our first conclusion was that T-IhNSC cells preserved all of the
characteristics of their parental hNSCs while, at the same time,
expressing a significantly faster kinetic expansion rate. the
extended proliferation and self-renewal capacity of this cell line
makes it amenable for at least 120 subculturing steps. This was
reflected in a significantly shorter, average doubling time, than
Figure 5. Analysis of proliferation decay during differentiation
and of neuronal subtypes in T58A differentiated cells. A) hNSC, c-
IhNSC, T-IhNSC and v-IhNSC cells were differentiated as described in
materials and methods. The percentage of residual proliferating cells
during differentiation was determined by immunofluorescence analysis
with a KI67 antibody. Upon mitogen removal, T-IhNSC cells progressively
cease to proliferate, reaching a terminal percentage of approximatively
4% of KI67+ cells (17 days in vitro). The number of total cells and
proliferating cells were counted in five randomly chosen fields from
duplicate experiments, after KI67 immunostaining. Data are expressed as
percentages of KI67+ cells ofthe total number of cells at different times of
differentiation. B) immunocolocalization of the neuronal marker b-
tubulinIII with the proliferative marker KI67 in T-IhNSC cultures at 10
days of differentiation. DAPI nuclear staining (blue) is also shown.
Magnification 206. C) Exemplar neuron from T-IhNSC cultures differen-
tiated at 17 days, fixed and immunostained with an antibody against
GABA. DAPI nuclear staining (blue) is also shown. Magnification 406.
doi:10.1371/journal.pone.0003310.g005
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longer than v-IhNSCs. Accordingly, while an average 25% of the
cells was engaged in S phase in all three immortalized cell lines, the
T-IhNSC cell line displayed a clonogenic potential similar to v-
IhNSCs and significantly higher than c-IhNSC cell line or parental
hNSCs [25,30]. This finding points to an increased viability and self-
renewal ability in T-IhNSCs and is in agreement with studies from
Cartwright et al. [12], showing that c-T58A promotes self-renewal
and maintenanceofpluripotencyinEScellsand thatthe T58A allele
in Burkitt’s lymphomas confers reduced apoptotic activity [13,16].
To date, T-IhNSC have been propagated for up to 120 passages
without any sign of senescence or proliferative decay or
transforming activity, which satisfies one of the requirements for
their classification as immortalized cell lines.
Consistent with the view that such immortalization was
conditional in its own nature, proliferation and self-renewal of
T-IhNSC remained strictly growth factor dependent, as shown
previously for normal hNSCs (Fig. 1B, 5A). Upon growth factor
removal, T-IhNSC underwent growth arrest and differentiation
and ceased divisions (Fig. 5A).
These findings show that, in association with a lower expansion
rate as compared to v-IhNSCs, T-IhNSCs display an earlier, safer
differentiation profile. In good keeping with the current view that
that T58A myc does not seem to act as an oncogene in brain cells,
these observations also provide support to the non-transformed
nature of the T-IhNSCs.
The latter was confirmed by the results of a soft-agar anchorage
independent colony formation assay in which, neither v-IhNSC
nor T-IhNSC or wt-IhNSC lines produced any colony, whereas
glioblastoma cells did so, as expected (Figure S5). In addition, the
intraparenchimal injection of T-IhNSC cells into SCID mice
brains, up to six months after transplantation, yielded no tumor
formation (data not shown). Although broader studies are required
to prove this point beyond any reasonable doubt, previous findings
cogently support this view. We have recently shown that, not even
v-IhNSCs could induce tumor formation when transplanted into
the brain parenchyma or intravenously into immunodeficient mice
[9,35]. Thus, if transformation does not take place when using the
v-myc gene, it is not unexpected that the c-myc T58A gene that we
used to establish T-IhNSCs, will be even less likely to bring about
transformation in human neural stem cells. In fact, unlike the c-
myc T58A gene that contains a single mutation and no proven
tumorigenic capacity, the v-myc role in oncogenesis has been
cogently shown in fibroblast and myeloid cells [23,24]. Further, it
has been proven that v-myc is much more effective than c-myc in
eliciting transformation, due to combinatorial effects of 59 and 39
mutations [36].
Another important feature of T-IhNSCs is that they retain the
multipotency typical of their parental cells, however with an
advantageous improved capacity to generate more neurons and
oligodendroglia, similar to v-IhNSCs. A review of the properties of
previously established immortalized cell lines and of their differen-
tiationcapacityshowsthattheselinesgenerateneuronsandastroglial
[5]. However, differentiation in these cells appeared to be regulated
bycues otherthan those normally observed innormal human neural
cells [31]. Unlike these lines, and similar to normal hNSCs and v-
IhNSCs [9], differentiation was a spontaneous event that ensued in
T-IhNSCs upon growth factor starvation. The overall amount of
neurons and astroglia generated by T-IhNSCs and v-IhNSCs were
comparable and significantly higher with respect to c-IhNSC cells
and hNSC cells (Fig. 3 A,B; Fig. 6A). Of note, these neurons
expressed the appropriate antigenic markers MAP5, b-tubulin III
and MAP2 and never colocalized with GFAP inside the same cells
(Fig. 2 a, c, e, g; Figure S2 a, d, g, l) – the latter being a likely sign of
transformation [30].
As hoped, T-IhNSC-derived neurons appeared to undergo
progressive maturation, spreading out long processes with varicos-
ities typical of mature dendrites, as shown previously for v-IhNSCs.
A preliminary characterization showed that the neuronal
neurotransmitter phenotype most represented amongst the T-
IhNSCs progeny was the GABAergic one, which appears to be a
somewhat default phenotype for cultured neural stem cells [31].
We are currently investigating if, similar to hNSCs, also T-IhNSCs
can be induced to generate catecholaminergic cells by exposure to
specific extracellular cues [31].
Regarding the ability to give rise to cells of the glial lineage, the
ability to give rise to bona fide oligodendrocytes is a pivotal feature in
cell lines that are applicable in the study of human neurogenesis, in
drug discovery and for modeling cell therapy for demyelinating
disorders. In this work we show that T-IhNSC display a vastly
increased capacity to give rise to human oligodendrocytes (up to
25.1% of the total cell number) that not only exceed that of their
parent hNSC cells (1–4% of the total cells; [25]) but is even
significantly greater of that observed in v-IhNSCs or c-IhNSCs
Figure 6. Morphological differentiation of premyelinating oligodendrocytes in differentiated T-IhNSC cells. A) Quantitative analysis of
the expression of the oligodendroglial markers GalC. Data are expressed as percentages of positive cells over total number of cells at 3, 10, 17 days of
differentiation. B) Exemplar oligodendrocytes obtained by T-IhNSC cells differentiation at 24 days in vitro. The oligodendroglial cells were labelled
with GalC. DAPI nuclear staining (blue) is also shown. Magnification 406.
doi:10.1371/journal.pone.0003310.g006
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morphological maturation of oligodendrocytes from T-IhNSC cells,
occurred as early as 17 days from the onset of differentiation (as
compared to 24 div in vIhNSC[9]), with the morphological features
of these cells approximating that of a fully mature oligodendrocyte
better than in any other cell (Fig. 2, b, d, f, h, Fig. 6B) This makes T-
IhNSC the cell line with the highest oligodendroglial developmental
potential to become available, to date.
Conclusions and remarks
In conclusion, our findings describe a new, continuous cell line of
human multipotent neural stem cells, that have been conditionally
immortalized using a mutant of c-myc never used in such an
endeavour before. Given that this gene has no known oncogenic
ability and bears a single, well-charaterized mutation as compared to
the standard immortalizing agent v-myc, the risk of transformation of
the targeted hNSCs is reduced. In fact, T-IhNSCs display no
transformation, but bear interesting characteristics, including rapid
expansion in culture, retention of growth-factor dependence, multi-
potentiality and stability over time. The complement of functional
features of T-IhNSCs are intermediate between those of previously
established v-IhNSCs and normal hNSCs. This provides a novel
model for the development of high throughput assays for both basic
and therapeutic studies on human neural cell development and a
valid human alternative to rodent cell lines for the identification of
neuroactive molecules targeting neurons and oligodendroglia.
The genuine multipotentiality of immortalized cells, their strict
growth factor dependence, the early appearance of differentiation
markers, and their rapid proliferation arrest after differentiation,
favours the T-IhNSC cell line for future clinical application studies.
In addition, T-IhNSCs may enable preliminary, broad screening
studies that could be subsequently confirmed and refined by utilizing
normal hNSCs. This represents a step towards elucidating many
unanswered questions in developmental human neurobiology.
Supporting Information
Figure S1 Proliferation and cell-cycle analyses. (A–D) BrdU
incorporation assay of in hNSC (A), c-IhNSC (B), T-IhNSC (C)
and v-IhNSC (D) cells. A pulse of BrdU was given to IhNSC cells
for 20 min and then the percentage of cells in S-phase was
identified by cytofluorimetric analysis. Actively proliferating cells
(in S-phase) are shown in the chart as the percentage of the
population BrdU+. (E) Analysis of the cell cycle duration showing
the relative time lengths (hours) of the different phases.
Found at: doi:10.1371/journal.pone.0003310.s001 (5.80 MB TIF)
Figure S2 Analysis of neuronal and glial markers expression
during differentiation. Immunofluorescence of hNSC (a–c), c-
IhNSC (d–f), T-IhNSC (g–i) and v-IhNSCs (l–n) cell line, showing
expression of cells lineage specific markers in cells differentiated for
10 days in adhesion on laminin in the absence of growth factors.
Astroglial cell marker GFAP is shown in green (a,d,g,l,c,f,i,n). The
neuronal markers MAP-5 is shown in red (a,d,g,l) and b-tubulinIII
in green (b,e,h,m). Astrocytes precursor marker, Vimentin, is
shown in red (b,e,h,m) and the oligondendrocytes marker, O4 is
shown in red (c,f,i,n). DAPI nuclear staining (blue) is also shown to
detect cells nuclei. Magnification 406.
Found at: doi:10.1371/journal.pone.0003310.s002 (7.36 MB TIF)
Figure S3 Asymmetric and symmetric divisions of T58A
progenitor cells. Panel A-B: immunofluorescence analysis of T-
IhNSC cells after 3 days in culture with FGF2 for glial (GFAP in
green), neuronal (b-tubulinIII in red). DAPI nuclear staining (blue)
is also shown. Panel A shows a symmetric division of a neuronal
unipotent progenitor. Panel B shows the segregation of b-
tubulinIII and GFAP in a bipotent neuroglial progenitor.
Found at: doi:10.1371/journal.pone.0003310.s003 (10.49 MB
TIF)
Figure S4 The differentiation potential of T58A stem cells.
Panel a–n: phase-bright microphotographs of hNSC (a–c), c-
IhNSC (d–f), T-IhNSC (g–i) and v-IhNSCs (l–n) cells attached to a
laminin-treated surface. Freshly dissociated neurospheres (a,d,g,l)
were cultured for 3 days in the presence of FGF2 (b, e, h and m)
and teminally differentiated in the absence of mitogenic factors (c,
f, i and n).
Found at: doi:10.1371/journal.pone.0003310.s004 (4.09 MB TIF)
Figure S5 Soft agar colony formation assay. IhNSC (A) cells
were seeded as a single cell suspension (1250 cells/well in a 24-
wells culture dish) in soft agar (0.4% in growth medium) and
incubated at 37uC, 5% CO2 as requested in the ‘‘Cell
Transformation Detection Assay’’ kit (CHEMICON n.
ECM570). Cells were analyzed using the cell stain solution
included with the kit to identify cell colony formation after 3
weeks. We could not detect cells colonies in wells containing
IhNSCs grown in these conditions. A glioblastoma cell line (GBM)
was used as positive control. GBM cells proliferated and produced
large clusters (B, 10.362.8 colonies/well).
Found at: doi:10.1371/journal.pone.0003310.s005 (0.88 MB TIF)
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